AN 721

Drug Profile

AN 721

Alternative Names: AN-721; NSD-721

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroSearch
  • Developer Aniona; Saniona
  • Class Analgesics; Anxiolytics
  • Mechanism of Action GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Inflammatory pain; Neuropathic pain; Pain
  • Discontinued Anxiety disorders

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Inflammatory-pain in Denmark
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Neuropathic-pain in Denmark
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top